Surgical patch TachoSil® planned to enter US market with partner Baxter Important milestone for Nycomed’s partnership strategy for the US market Nycomed grants Baxter International Inc......
Marketing authorisation application filed for Europe through the Centralised Procedure Treatment aimed at opioid tolerant patients with cancer experiencing breakthrough pain Strengthening the Nycomed pain control portfolio Nycomed filed a marketing authorisation application with the European Medicines Agency (EMEA) for an intranasal fentanyl spray in Europe on December 7, 2007......
Net turnover increases by 4.9% for the first nine months of 2007 29.4% increase in adjusted EBITDA Strong margin growth and reduced spending Integration of Altana Pharma ahead of plan with positive effect on business opportunities and spending levels Bid for Bradley Pharmaceuticals Teduglutide in-licensed The financial results reported in this press release are related to Nycomed S......
Acquisition will add to the branded dermatologic line as a growth driver for the future Integration of Bradley will provide an enhanced platform for in-licensing and co-promotion of dermatology products Bradley Pharmaceuticals will be integrated with the PharmaDerm and Fougera divisions of Nycomed’s US specialty business Combined sales of Nycomed US and Bradley amount to approximately €320 million/$450 million on an annualised basis Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc......
Nycomed acquires exclusive rights outside North America GATTEX™ matches Nycomed’s capabilities in gastroenterology Total upfront payments of $35 million and potential for more than $150 million milestone payments Nycomed and NPS Pharmaceuticals, Inc......
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey denied Nycomed’s and Wyeth’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......
The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006......
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey has taken the matter of Wyeth and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......
Nycomed and its partner NPS Pharmaceuticals announced today that they have entered an agreement expanding and amending rights and responsibilities under the Preotact® (full-length parathyroid hormone [PTH 1-84]) license originally entered into in 2004......
Today Nycomed announced that its partner Neurim Pharmaceuticals EEC, the EU subsidiary of Neurim Pharmaceuticals Ltd has received a European Marketing Authorisation for Circadin® 2 mg (prolonged release melatonin)......